

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: MEDLAND, Peter, et al.

Serial No.: To Be Assigned  
(371 National Phase Application of PCT/GB2005/000779)  
(Published as WO 2005/085244)

Filed: Herewith

For: 3,5-disubstituted 1H-pyrrolo [2,3-B] pyridines as JNK Inhibitors

Attorney Docket No.: 102286.167 US1

**PRELIMINARY AMENDMENT**

**EXPRESS MAIL LABEL NO.: EV 604749793 US**  
**September 1, 2006**

MAIL STOP PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Prior to the examination of the above-identified application on the merits, please amend above-identified specification and claims as follows:

**Amendments to the Specification** begin on page 2 of this paper.

**Amendments to the Claims** are reflected in the listing of claims which begins on page 3 of this paper.

**Remarks** begin on page 31 of this paper.